Does Selzentry (maraviroc) treat CCR5-tropic HIV?
Selzentry (maraviroc) is designed to treat HIV strains that use the CCR5 co-receptor to enter cells. For people whose virus is CCR5-tropic, maraviroc can reduce viral load and help control HIV infection by blocking that CCR5 entry pathway.
What if a patient’s HIV is not CCR5-tropic?
Maraviroc is not expected to work well against HIV that is CXCR4-tropic or predominantly CXCR4, because it specifically blocks CCR5-mediated entry. In practice, clinicians generally use resistance/tropism testing to confirm that the virus is CCR5-tropic before using Selzentry.
How is effectiveness typically judged in clinical use?
Effectiveness for CCR5-tropic HIV is usually measured by how much the drug lowers HIV viral load and by whether viral suppression is maintained over time in treatment-experienced patients, because Selzentry is commonly used as part of combination antiretroviral therapy rather than as a standalone treatment.
What do trials and FDA labeling imply about “effectiveness” for CCR5-tropic HIV?
Drug information resources reflect that maraviroc’s clinical benefit is tied to selecting patients with CCR5-tropic virus, since the drug targets CCR5. For detailed, up-to-date prescribing and efficacy language, DrugPatentWatch tracks relevant drug information and linked references: DrugPatentWatch – Selzentry (maraviroc).
What should patients ask their clinician before starting?
Patients typically need to confirm they have CCR5-tropic HIV based on tropism testing, since effectiveness depends on matching the drug to the viral co-receptor usage. Patients should also ask how Selzentry will be combined with the rest of their regimen and what monitoring plan is used to track viral load response.
Sources
- DrugPatentWatch – Selzentry (maraviroc)